17/07/2020
Orphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the...
08/07/2020
VAXIMM Appoints Thomas D. Szucs, MD, as Chairman of the Board VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced the appointment of Thomas D. Szucs, MD, as Chairman of the Supervisory Board. He succeeds Thomas...
02/07/2020
Ascelia Pharma completes a directed new share issue of 4,697,781 shares, raising approximately SEK 98.7 million Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has, based on the authorisation granted by the annual general meeting on 6 May...
02/07/2020
Orphazyme announces confidential submission of a draft registration statement for a potential registered public offering in the United States Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company harnessing the amplification of the...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments